Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative Transcriptomic Signature of tRNA-Derived Fragment Targets and Lactylation-Related Genes for Prostate Cancer Diagnosis.

Cancer medicine·2026
Same author

Tumour Single-Cell Bioinformatics: From Immune Profiling to Molecular Dynamics.

Journal of cellular and molecular medicine·2025
Same author

PA suppresses antitumor immunity of T cells by disturbing mitochondrial activity through Akt/mTOR-mediated Ca<sup>2+</sup> flux.

Cancer letters·2023
Same author

Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.

Cancer immunology research·2023
Same author

Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs.

Journal of cancer research and clinical oncology·2022
Same author

Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer.

Pharmacological research·2021

Related Experiment Video

Updated: May 7, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

1.0K

Enhancing CAR-T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF-Mediated Angiogenesis.

Shishuo Sun1,2,3, Qihong Li1,2,3, Bixi Wang1,3

  • 1Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|May 6, 2026
PubMed
Summary

CAR-T cell therapy shows promise for solid tumors. A study found CAR-T cells can promote tumor growth via CCL5, but blocking this enhances efficacy, suggesting new treatment strategies.

Keywords:
CAR‐TCCL5VEGFsolid tumortumor angiogenesis

More Related Videos

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.6K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

19.9K

Related Experiment Videos

Last Updated: May 7, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

1.0K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.6K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

19.9K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Chimeric antigen receptor-modified T cells (CAR-T) are effective against blood cancers but show limited efficacy in solid tumors.
  • The tumor microenvironment (TME) presents non-specific barriers to CAR-T cell function.

Purpose of the Study:

  • To investigate the dose-dependent impact of CAR-T cells on solid tumor growth.
  • To elucidate the mechanisms by which CAR-T cells influence the TME and tumor progression.
  • To identify strategies for enhancing CAR-T cell efficacy in solid tumors.

Main Methods:

  • Utilized multiple mouse models to assess CAR-T cell therapy.
  • Analyzed the dual role of tumor-infiltrating CAR-T cells, including cytokine and chemokine production.
  • Investigated the role of CCL5 in promoting tumor growth and angiogenesis.
  • Tested combination therapy using CCL5-knockout CAR-T cells and CCR5 inhibitors.

Main Results:

  • CAR-T cell impact on tumor growth is dose-dependent, ranging from promotion to inhibition.
  • Tumor-infiltrating CAR-T cells release antitumor molecules (IFN-γ, TNF-α) but also CCL5.
  • CCL5 produced by CAR-T cells promotes tumor growth by inducing VEGF and angiogenesis.
  • Combination therapy with CCL5-knockout CAR-T cells and maraviroc significantly improved antitumor efficacy.

Conclusions:

  • CCL5-mediated protumor activity is a key limitation for CAR-T cell therapy in solid tumors.
  • Targeting CCL5 and its receptor CCR5 offers a promising strategy to enhance CAR-T cell efficacy.
  • These findings pave the way for improved combination therapies against solid tumors.